Higher nuclear HSF1 expression has been shown to strongly correlate with poor prognosis in patients with estrogen receptor positive (ER+) [117], human epidermal growth factor receptor 2 positive (HER2+), and triple-negative breast cancer [118]. Here, ERBB2 is linked to triple-negative breast carcinoma.